Personalis Inc (PSNL)

Personalis, Inc. is a healthcare company focused on advanced cancer genomics. It develops and commercializes testing and related services in the United States and international markets, with a portfolio that includes NeXT Personal, a tumor-informed liquid biopsy test used for minimal residual disease detection, therapy response assessment, and recurrence monitoring in solid tumors. The company also offers ImmunoID NeXT, a tissue-based service that combines whole exome and whole transcriptome sequencing with analytics to provide a detailed view of the tumor and its microenvironment from a single sample. Additional offerings include NeXT Personal Dx and NeXT Dx, along with sequencing services for diagnostic companies and research projects. Personalis serves pharmaceutical, biopharmaceutical, diagnostics, academic, nonprofit, government, and patient customers, and it has a strategic collaboration with Tempus AI to support testing for colorectal cancer patients. The company was incorporated in 2011 and is headquartered in Fremont, California.

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.